The hs-CRP is a marker of inflammation, and the FOURIER study (Further Cardiovascular Outcomes Research with PCSK9 Inhibitor in Patients with Elevated Risk) showed that the hs-CRP level can predict the risk of various cardiovascular diseases, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for acute coronary syndrome, and coronary revascularization [20]. Here, PCSK9 is linked to acute coronary syndrome.